IDH1 & IDH2 Mutation Analysis

Overview

  • EPIC Code:
  • N/A
  • Soft Test Code:
  • PS
  • Send Out Test Code:
  • Soft Path - IDH1 & IDH2
Alternate Names
  • IDH1 Mutation Analysis
  • IDH2 Mutation Analysis
Included Tests

IDH1 Mutation Analysis; IDH2 Mutation Analysis


Clinical Significance

IDH1 or IDH2 mutations are detected in approximately 15-20% of acute myeloid leukemia (AML) and >70% grade II or III brain gliomas. Patients with AML and mutations are likely to have aggressive disease, while mutations in gliomas are associated with better prognosis. Long-term survival after aggressive tumor resection has been reported for patients with IDH1-positive astrocytomas


Specimen Collection & Preparation

Specimen Requirements

FFPE tissue: Paraffin block


Transport And Storage

Refrigerate, and use cold pack for transport, cold pack should not be in direct contact with specimen


Collection Instructions

Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.


Minimum Volume


Neonatal Volume

Clinical Interpretation

Reference Range:

Refer to Interpretive Results


Methodology:
  • Molecular
Clinical Significance

IDH1 or IDH2 mutations are detected in approximately 15-20% of acute myeloid leukemia (AML) and >70% grade II or III brain gliomas. Patients with AML and mutations are likely to have aggressive disease, while mutations in gliomas are associated with better prognosis. Long-term survival after aggressive tumor resection has been reported for patients with IDH1-positive astrocytomas


Production Schedule

Sites Performed
  • NeoGenomics
Departments
  • Sendouts - Pathology
Turn Around Time

7 to 8 days


Coding & Compliance

CDM

00918891, 00918892


CPT Coding

81120, 81121